French Association of Outsourcing and Innovative Companies
in the field of Life Sciences

The "Association Française des Sociétés de Services et d'Innovation (AFSSI)", French Association of Outsourcing and Innovative Companies in the field of Life Sciences was born in 2012 to gather companies established in France and providing R&D services to industrial or academic partners. It is a non-profit organization (Association Loi de 1901) headquarter in Romainville (FR-93230). AFSSI embraces the domain of Life Sciences at large: Biotechnology, Fine Chemistry, Cosmetology, Agro-food, Bioinformatics, Diagnostics, Clinical trials, Green business.

AFSSI represents companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs on behalf of third parties. They manage a long term process to support their growth.

AFSSI provides advocacy, internal relationships, communications services for the members both large and small companies.

AFSSI entrepreneurs are consistent operators of life science development known as the new frontier of industry. Thanks to their know how and professionalism they make easier and faster the market access of innovative products in pharmacy, cosmetology, agro-food, etc.

AFSSI challenges are driven by the vision of life science companies as top players of french international competition. AFSSI works toward enriching the Life sciences industry with networking, partering and education opportunities.

Sector Key Figures
300 French companies
1 billion €
9400 employees

Our companies


Based upon the "open innovation" paradigm in use in a growing number of industry, AFSSI aims at ruling new relationships between providers and customers as inspired by the European Small Business Act. AFSSI is playing the role of an organizer of the french industrial Life Sciences network.

 

AFSSI members are companies:

  • Managed as entrepreneurship long term processes;
  • With sharp cutting edge technologies installed in top ranking premises;
  • Running QA-driven R&D programs fulfilling international guidelines;
  • Able to set up flexible processes to shape customer expectations;
  • Une relation type « collaborateur/partenaire »
  • Present as partners better than sub-contractors;
  • Investing consistently in R&D and source of revolving PI.

Haut de page

Elected Board Members



Honorary president

Philippe GENNE,
PDG, Oncodesign

President

Xavier MORGE,
DG, Bertin Pharma

Vice-president

Jean-François LE BIGOT,
PDG, CiToxLAB

General Delegate

Claude-Alain CUDENNEC,

Treasurer

Michel PAUTRAT,
Co-founder, Cell&Co
Haut de page

           
Priorities


AFSSI aims at highlighting the key role of its members in the future economy and drawing the attention of governmental and industrial decision makers to strongly support this growing business.

AFSSI was mandated to contribute as a partner to the development of Life Sciences clusters in France, to become a recognized counterpart of regulatory bodies acting in the field, to set up new ethical and deontological rules in the business relationships.


Haut de page

Mode of Action


AFSSI is managed by a six-membered elected board. A General Delegate and a Secretary run the day-to-day activities. Six ad hoc Committees develop thematic programs to be adopted by the board.


AFSSI intend to organize twice a year Symposia in order to strengthen the communication of its programs and the relationships with government and industry stakeholders.

Haut de page
 
  • 4SBio
  • ACOBIOM
  • ADVANCED BIODESIGN
  • Agro-Bio
  • AMYLGEN
  • ANAQUANT
  • ANM PARTNERS
  • ANS Biotech
  • APTYS Pharmaceuticals
  • ART IMMUNE
  • ATLANBIO
  • ATLANCHIM PHARMA
  • ATLANGRAM
  • Atlantic Bone Screen
  • AXENIS
  • AZELEAD
  • Banook Central Imaging
  • BCI Pharma
  • BERTIN PHARMA
  • BGene Genetics
  • BIOALTERNATIVES
  • BIODOXIS
  • BioGalenys
  • BIOMEOSTASIS
  • CAPEVAL
  • CDL PHARMA
  • CELL CONSTRAINT CANCER
  • CELL&CO
  • CELLVAX
  • CELENYS
  • centrecap
  • CERB
  • Chelatec
  • Cilcare
  • CILOA
  • CiToxLAB
  • CLEAN CELL
  • COHIRO
  • CTI BIOTECH
  • COVALAB
  • CYBERNANO
  • CYNBIOSE
  • DIVERCHIM
  • DRUGABILIS
  • E2DG
  • eVeDrug
  • EXCILONE
  • FLOWCHEM
  • GENEPEP
  • GENOSAFE
  • GENOSCREEN
  • GENOSPLICE
  • GTP
  • HISTALIM
  • HCS Pharma
  • HYBREGENICS SERVICES
  • IMAVITA
  • IMSTAR
  • INOVOTION
  • IRIS Pharma
  • ITEC SERVICES
  • KALLISTEM
  • KALY-CELL
  • KEY-OBS
  • L2D
  • LPS Biosciences
  • MABSOLYS
  • METABOLYS
  • MODUL-BIO
  • MITOLOGICS
  • NEURON EXPERTS
  • NEUROSERVICE
  • NEURO SYS
  • NOVOTEC
  • NS Repair
  • NVH MEDICINAL
  • ONCODESIGN
  • ONCOMEDICS
  • Oncovet Clinical Research
  • OROXCELL
  • OXELTIS
  • PHARMASPECIFIC
  • PHATOPHY
  • PhinC
  • PHYLOGENE
  • PHYSIOGENEX
  • PHYSIOSTIM
  • Phytosafe
  • PLATINE
  • POPSICUBE
  • PORSOLT
  • PRIMADIAG
  • PROFILOMIC
  • Proteodynamics
  • PROVOTECH
  • PROVEPEP
  • PX'THERAPEUTICS
  • QUANTACELL
  • RD-BIOTECH
  • ROOWIN
  • SLEEP APNEA BIOTECH INNOVATION
  • SMALTIS
  • synkem
  • SKULDTECH
  • SOLADIS
  • SYNAPCELL
  • SYNTHELIS
  • TETRAHEDRON
  • THERADIS PHARMA
  • TKM
  • VEBIO
  • VIVEXIA
  • VOISIN CONSULTING
  • VOXCAN
  • XENTECH
  • X'PROCHEM